Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Novo Nordisk expects to file for the first regulatory approval ... CagriSema is a fixed-dose combination of a long-acting ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...